219 related articles for article (PubMed ID: 9219317)
1. Differentiating among nonsteroidal antiinflammatory drugs by pharmacokinetic and pharmacodynamic profiles.
Fenner H
Semin Arthritis Rheum; 1997 Jun; 26(6 Suppl 1):28-33. PubMed ID: 9219317
[TBL] [Abstract][Full Text] [Related]
2. Development of in vitro assays for the evaluation of cyclooxygenase inhibitors and predicting selectivity of nonsteroidal anti-inflammatory drugs in cats.
Giraudel JM; Toutain PL; Lees P
Am J Vet Res; 2005 Apr; 66(4):700-9. PubMed ID: 15900953
[TBL] [Abstract][Full Text] [Related]
3. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays.
Riendeau D; Charleson S; Cromlish W; Mancini JA; Wong E; Guay J
Can J Physiol Pharmacol; 1997 Sep; 75(9):1088-95. PubMed ID: 9365818
[TBL] [Abstract][Full Text] [Related]
5. Meloxicam: selective COX-2 inhibition in clinical practice.
Furst DE
Semin Arthritis Rheum; 1997 Jun; 26(6 Suppl 1):21-7. PubMed ID: 9219316
[TBL] [Abstract][Full Text] [Related]
6. Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity.
Lazer ES; Miao CK; Cywin CL; Sorcek R; Wong HC; Meng Z; Potocki I; Hoermann M; Snow RJ; Tschantz MA; Kelly TA; McNeil DW; Coutts SJ; Churchill L; Graham AG; David E; Grob PM; Engel W; Meier H; Trummlitz G
J Med Chem; 1997 Mar; 40(6):980-9. PubMed ID: 9083488
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1.
Ogino K; Hatanaka K; Kawamura M; Katori M; Harada Y
Pharmacology; 1997 Jul; 55(1):44-53. PubMed ID: 9309800
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action of aspirin-like drugs.
Vane JR; Botting RM
Semin Arthritis Rheum; 1997 Jun; 26(6 Suppl 1):2-10. PubMed ID: 9219313
[TBL] [Abstract][Full Text] [Related]
9. Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use.
Blain H; Boileau C; Lapicque F; Nédélec E; Loeuille D; Guillaume C; Gaucher A; Jeandel C; Netter P; Jouzeau JY
Br J Clin Pharmacol; 2002 Mar; 53(3):255-65. PubMed ID: 11874389
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview.
Famaey JP
Inflamm Res; 1997 Nov; 46(11):437-46. PubMed ID: 9427063
[TBL] [Abstract][Full Text] [Related]
11. Review article: COX-II inhibitors--a new generation of safer NSAIDs?
Donnelly MT; Hawkey CJ
Aliment Pharmacol Ther; 1997 Apr; 11(2):227-36. PubMed ID: 9146759
[TBL] [Abstract][Full Text] [Related]
12. In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study.
King JN; Rudaz C; Borer L; Jung M; Seewald W; Lees P
Res Vet Sci; 2010 Jun; 88(3):497-506. PubMed ID: 20004922
[TBL] [Abstract][Full Text] [Related]
13. Effect of selective vs. non-selective cyclo-oxygenase inhibitors on fetal membrane prostaglandin synthesis.
Sawdy R; Pan H; Sullivan M; Bennett P
J Obstet Gynaecol; 2003 May; 23(3):239-43. PubMed ID: 12850850
[TBL] [Abstract][Full Text] [Related]
14. Meloxicam inhibits prostaglandin E(2) generation via cyclooxygenase 2 in the inflammatory site but not that via cyclooxygenase 1 in the stomach.
Ogino K; Hatanaka K; Kawamura M; Ohno T; Harada Y
Pharmacology; 2000 Nov; 61(4):244-50. PubMed ID: 11093076
[TBL] [Abstract][Full Text] [Related]
15. Preferential inhibition of cyclooxygenase-2 by meloxicam in human rheumatoid synoviocytes.
Tsubouchi Y; Sano H; Yamada R; Hashiramoto A; Kohno M; Kusaka Y; Kondo M
Eur J Pharmacol; 2000 May; 395(3):255-63. PubMed ID: 10812057
[TBL] [Abstract][Full Text] [Related]
16. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects.
Panara MR; Renda G; Sciulli MG; Santini G; Di Giamberardino M; Rotondo MT; Tacconelli S; Seta F; Patrono C; Patrignani P
J Pharmacol Exp Ther; 1999 Jul; 290(1):276-80. PubMed ID: 10381787
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the effects of nabumetone vs meloxicam on serum thromboxane B2 and platelet function in healthy volunteers.
van Kraaij DJ; Hovestad-Witterland AH; de Metz M; Vollaard EJ
Br J Clin Pharmacol; 2002 Jun; 53(6):644-7. PubMed ID: 12047490
[TBL] [Abstract][Full Text] [Related]
18. [Clinical application of cyclooxygenase-2 inhibitors].
Dzielska-Olczak M; Olczak S
Pol Merkur Lekarski; 2001 Jun; 10(60):480-2. PubMed ID: 11503270
[TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs.
Cryer B; Feldman M
Am J Med; 1998 May; 104(5):413-21. PubMed ID: 9626023
[TBL] [Abstract][Full Text] [Related]
20. [New NSAIDS: COX-1, COX-2, what about them?].
Peretz A
Rev Med Brux; 1998 Sep; 19(4):A399-402. PubMed ID: 9805982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
